“Global Cell Therapy Technologies market set to grow to $23bn by 2024” says new Visiongain report

19 February 2020
Pharma

Visiongain has launched a new pharma report Cell Therapy Technologies Market Report: Consumables, Equipment, System & Software, Cell Processing, Cell Processing Equipment, Single Use Equipment, Cell Preservation, Distribution, Handling, Process Monitoring & Quality Control, Human Cells, Animal Cells, Life Sciences & Research Companies, Research Institutes.

Cell therapy technology is one of the fastest growing markets and is an ever-changing landscape. It represents the umbrella of recent advancement in the field of gene therapy, drug delivery, cancer vaccines, various application of stem cells, regenerative medicine, and tissue engineering. Higher government investments for cell-based research, availability of advanced cell therapy technologies and growing demand of cell therapies are expected to further propel the market growth.

The lead analyst of the report commented "Cell therapy technologies are used across various research areas including gene therapy, cancer vaccines, regenerative medicine, biologics and others. Increasing global disease burdens and the need for more personalised & precision medicine has led to massive growth in the cell technology market, which is likely to increase over the next decade. While the global market will experience significant growth, the Asia Pacific region is expected to be the fastest growing submarket, primarily due to the presence of large numbers of Clinical Research Organisations (CROs) in the region. The main restraints of growth in this market are the complex regulations and ethical issues governing cell therapy research, which have limited the number of clinical trials approved. However, this is being countered by innovative technologies from manufacturers, which are increasingly solving the challenges of scalability and safety associated with cell therapies."

Leading companies featured in the report include Thermo Fisher Scientific, Inc., Merck KGaA, Terumo Bct, Inc., Lonza Group, GE Healthcare and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever